Compound ID | 182
Class: Pleuromutilin
| Spectrum of activity: | Gram-positive & Gram-negative |
| Details of activity: | S. aureus (MSSA, MRSA) and S. pneumoniae, along with E.coli, K.pneumoniae and E.cloacae |
| Propensity to select resistant mutants: | Yes |
| Institute where first reported: | Nabriva Therapeutics, Austria |
| Year first mentioned: | 2010 |
| Highest developmental phase: | Preclinical |
| Development status: | Active |